Tu Diep, Skye Bioscience's COO discusses his lifelong passion, interest and work leading up to the clinical drug development journey of lead asset nimacimab.
Skye’s CEO and CMO get perspectives from three obesity specialists regarding our imminent CBeyondTM Phase 2a clinical trial data and new preclinical results.
Skye’s CMO and CSO discuss key differentiating mechanistic components of our peripherally-restricted CB1-inhibiting antibody, nimacimab.
This research characterized advantages of nimacimab versus the small molecule CB1 inhibitor, nimacimab, in terms of weight loss and rebound.
This research characterized benefits of the combination of nimacimab and tirzepatide versus either drug alone in terms of weight rebound and maintenance.
This research characterized benefits of the combination of nimacimab and tirzepatide versus either drug alone in terms of weight rebound and maintenance.
In this intro and overview of Skye's Anatomy of Progress video series, we highlight Skye’s positioning and progress in obesity therapeutic drug development, noting the differentiation of its allosteric modulating antibody that takes into consideration fat metabolism, safety and long-term care.
A review of Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.
A review of Skye’s current clinical activity and near-term path to Phase 2a data.
Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with the target product profile of a peripherally-restricted CB1 inhibitor such as nimacimab.